Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO E-Learning: Targeting Angiogenesis in Ovarian Cancer

New module by Dr Sandro Pignata and Dr Sabrina Chiara Cecere out now. View the presentation and, if you are an ESMO member, take the CME test!

Learning objectives

  • To provide an update on the role of angiogenesis and the importance of its targeting in the management of patients with ovarian cancer
  • To provide an update on anti-angiogenic targets and compounds, currently approved for treatment of ovarian cancer or under development
  • To provide an update from clinical studies with anti-angiogenic therapies in first-line setting, platinum-sensitive and platinum-resistant recurrent ovarian cancer

After two years E-Learning modules are no longer considered current. There is therefore no CME test associated with this E-Learning module.

Title Duration Content CME Points CME Test
Targeting Angiogenesis in Ovarian Cancer 31 min. 53 slides - -

Therapeutic targeting of angiogenesis is one of the most intensive areas in drug research today. Bevacizumab was the first targeted agent and currently remains the only anti-angiogenic drug approved for use in patients with ovarian cancer. Despite this drug’s approval, there is a general impression that it is still underused in the oncology practice.

Therefore, this module on targeting the angiogenesis, with a comprehensive overview of different targets, targeting strategies and anti-angiogenic compounds, is timely released. It provides an excellent review of drugs activity and clinical outcomes in different settings of ovarian cancer.

In the first-line setting bevacizumab prolongs progression-free survival (PFS). Clinical trials with tyrosine kinase inhibitors showed prolonged PFS when they are given concurrently with chemotherapy in case of nindetanib or as maintenance in case of pazopanib. Other drugs are under investigation.

In terms of platinum-sensitive recurrent ovarian cancer, when given with chemotherapy, bevacizumab prolongs PFS. Prematurely closed study with cediranib’s combination with chemotherapy showed prolonged PFS and overall survival. There is no data in patients pretreated with bevacizumab. Treatment with bevacizumab beyond progression is currently under evaluation.

In terms of platinum-resistant recurrent ovarian cancer, bevacizumab and trebanabib, both in combination with chemotherapy, prolong PFS. A combination of anti-angiogenic drug with weekly paclitaxel seems to be the most effective. Multiple agents are under investigation and as in the platinum-sensitive disease there is no data in patients pretreated with bevacizumab.

The authors conclude that anti-angiogenic drugs are active in first-line and maintenance setting, resistant and sensitive disease, with no doubt that targeting the angiogenesis is crucial in ovarian cancer. However, no predictive biomarker has been identified. They predict that 3-4 different anti-angiogenic agents might be approved in the future. Currently, there is no available data on sequences, treatment beyond progression or cross resistance. These areas remain to be addressed by ongoing and future research.

This E-Learning module is an excellent CME opportunity for all oncologists with interest in gynaecologic malignancies and those keen to learn essential updates from the latest data in this area of clinical cancer research.

This E-Learning module was published in 2014 and expired in 2017.

Last update: 19 Sep 2014

The authors have reported no conflict of interest

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings